/CNW/ - Health Canada has accepted a New Drug Submission (NDS) for nirsevimab, the first investigational single-dose long-acting antibody designed for all.
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial - read this article along with other careers information, tips and advice on BioSpace
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy infants1,2Nirsevimab is the first investigational immunization designed to protect all infants across th.
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.